Varian Medical announces its support for a 1st-of-its kind clinical trial comparing radiosurgery to surgery in patients with operable non-small cell lung cancer.

Varian Medical (NYSE:VAR) joined forces with the National Cancer Institute to support a Phase III clinical trial comparing radiosurgery with surgical resection in treatment of non-small cell lung cancer.

The trial will compare non-invasive radiosurgical treatment with surgery in early-stage, high-risk, operable patients, according to a press release.